The “fate” of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of blood–brain barrier crossing and trafficking into the central nervous system

Abstract Drug delivery to the brain represents one of the most important challenges in the field of nanomedicine, as the study and planning of nanocarriers able to cross the blood brain barrier are topics at the cutting edge of technology and innovation. In this review, we analyze the interventions and progresses in the field, by analyzing the choice of the polymer, of the ligands and the main relevant in vivo and in vitro experiments. A critical overview of these aspects will help in better understanding the status of nanomedicine in the application to central nervous system pathologies along with the future directions.

[1]  M. Walker,et al.  Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. , 1999, Pharmacology & therapeutics.

[2]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[3]  Barbara Ruozi,et al.  Development of Novel Zn2+ Loaded Nanoparticles Designed for Cell-Type Targeted Drug Release in CNS Neurons: In Vitro Evidences , 2011, PloS one.

[4]  W. Pardridge,et al.  Antisense gene therapy of brain cancer with an artificial virus gene delivery system. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  W. Pardridge.  Why is the global CNS pharmaceutical market so under-penetrated? , 2002, Drug discovery today.

[6]  R. Pignatello,et al.  New Amphiphilic Conjugates of Amino–Poly(ethylene glycols) With Lipoamino Acids as Surface Modifiers of Colloidal Drug Carriers , 2013 .

[7]  S. Dow,et al.  Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes , 2004, Cancer Immunology, Immunotherapy.

[8]  Jian Yi Li,et al.  Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. , 2003, Molecular vision.

[9]  W. Pardridge,et al.  Receptor-Mediated Gene Targeting to Tissues In Vivo Following Intravenous Administration of Pegylated Immunoliposomes , 2001, Pharmaceutical Research.

[10]  J. Huwyler,et al.  Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. , 1997, The Journal of pharmacology and experimental therapeutics.

[11]  R. Acquaviva,et al.  In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain , 2011, Drug development and industrial pharmacy.

[12]  M. Zoli,et al.  Brain-targeted polymeric nanoparticles: in vivo evidence of different routes of administration in rodents. , 2013, Nanomedicine.

[13]  James P Basilion,et al.  Nanoparticles for imaging and treating brain cancer. , 2013, Nanomedicine.

[14]  D. Begley,et al.  Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles , 2003, Pharmaceutical Research.

[15]  Michele Zoli,et al.  Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[16]  C. Emiliani,et al.  Use of Polylactide-Co-Glycolide-Nanoparticles for Lysosomal Delivery of a Therapeutic Enzyme in Glycogenosis Type II Fibroblasts. , 2015, Journal of nanoscience and nanotechnology.

[17]  W. Pardridge,et al.  Brain-specific expression of an exogenous gene after i.v. administration , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Boeckers,et al.  Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release. , 2014, International journal of pharmaceutics.

[19]  P. Couvreur,et al.  Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.

[20]  M. Morari,et al.  Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine , 2008, Pharmaceutical Research.

[21]  Miqin Zhang,et al.  Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. , 2009, Cancer research.

[22]  S. Liebner,et al.  Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme , 2000, Acta Neuropathologica.

[23]  B. Davidson,et al.  The FASEB Journal express article 10.1096/fj.01-0421fje. Published online November 29, 2001. , 2022 .

[24]  W. Pardridge,et al.  Drug and gene targeting to the brain with molecular trojan horses , 2002, Nature Reviews Drug Discovery.

[25]  C. Mancuso,et al.  Trans-ferulic acid-based solid lipid nanoparticles and their antioxidant effect in rat brain microsomes. , 2013, Colloids and surfaces. B, Biointerfaces.

[26]  C. Hsu,et al.  Future prospects of nanoparticles on brain targeted drug delivery , 2009, Journal of Neuro-Oncology.

[27]  Changsheng Xie,et al.  Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. , 2004, Biomaterials.

[28]  R. Müller,et al.  Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  B. Sabel,et al.  Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice. , 2000, Life sciences.

[31]  Mansoor M Amiji,et al.  Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases , 2009, Expert opinion on drug delivery.

[32]  M. Nedergaard,et al.  The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.

[33]  M. Ricci,et al.  Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. , 2013, International journal of pharmaceutics.

[34]  H. Federoff,et al.  Novel targets for CNS gene therapy , 1999, Gene Therapy.

[35]  R. Pignatello,et al.  Effects of external phase on D-cycloserine loaded W/O nanocapsules prepared by the interfacial polymerization method. , 2011, European journal of medicinal chemistry.

[36]  Yan Zhang,et al.  Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[37]  Giuseppe Trapani,et al.  Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. , 2011, International journal of pharmaceutics.

[38]  G. Romano,et al.  Lipid nanoparticles for brain targeting II. Technological characterization. , 2013, Colloids and surfaces. B, Biointerfaces.

[39]  G. Filice,et al.  Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[40]  Xinguo Jiang,et al.  Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[41]  M. Masserini,et al.  Liposomes functionalized to overcome the blood–brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model , 2013, International journal of nanomedicine.

[42]  Russell J Mumper,et al.  Brain uptake of thiamine-coated nanoparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[43]  G. Frasca,et al.  Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[44]  A. Trapani,et al.  In vitro evaluation on a model of blood brain barrier of idebenone-loaded solid lipid nanoparticles. , 2012, Journal of nanoscience and nanotechnology.

[45]  J. Folkman,et al.  Tumor angiogenesis: a quantitative method for histologic grading. , 1972, Journal of the National Cancer Institute.

[46]  G. Vassal,et al.  Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[47]  R. Gabathuler,et al.  Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.

[48]  D. Begley,et al.  Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[49]  W. Shyu,et al.  Simultaneous High-Performance Liquid Chromatographic Analysis of Cefprozil Diastereomers in a Pharmacokinetic Study , 1991, Pharmaceutical Research.

[50]  B. Ruozi,et al.  Nanomedicine: the future for advancing medicine and neuroscience. , 2012, Nanomedicine.

[51]  W. Lu,et al.  Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. , 2006, Cancer research.

[52]  M. Masserini,et al.  The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. , 2011, Biomaterials.

[53]  V. Cardile,et al.  Evaluation of new amphiphilic PEG derivatives for preparing stealth lipid nanoparticles , 2013 .

[54]  J. Kreuter.  Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. , 2004, Journal of nanoscience and nanotechnology.

[55]  Patrick Couvreur,et al.  Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. , 2005, Bioconjugate chemistry.

[56]  Yan Zhang,et al.  Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[57]  S. Rapoport,et al.  An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.

[58]  D D Allen,et al.  Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier , 2002, Drug development and industrial pharmacy.

[59]  M. Zucchetti,et al.  Do anticancer agents reach the tumor target in the human brain? , 2004, Cancer Chemotherapy and Pharmacology.

[60]  G. Tosi,et al.  Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[61]  M. Masserini,et al.  Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[62]  R. Mumper,et al.  Paclitaxel nanoparticles for the potential treatment of brain tumors. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[63]  T. Suhara,et al.  Pharmacokinetics and brain uptake of lactoferrin in rats. , 2006, Life sciences.

[64]  D. A. Kharkevich,et al.  Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles , 1995 .

[65]  Giovanni Puglisi,et al.  The critical role of didodecyldimethylammonium bromide on physico-chemical, technological and biological properties of NLC. , 2014, Colloids and surfaces. B, Biointerfaces.

[66]  Y. Kajimoto,et al.  Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy , 2008, Journal of Neuro-Oncology.

[67]  M. Menger,et al.  Vascular Microenvironment in Gliomas , 2000, Journal of Neuro-Oncology.

[68]  D. Paolino,et al.  A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB , 2010, Neuroscience Letters.

[69]  M. Zoli,et al.  PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting. , 2015, Nanomedicine.

[70]  C. Puglia,et al.  Lipid nanoparticles for brain targeting I. Formulation optimization. , 2011, International journal of pharmaceutics.

[71]  Qing X. Yang,et al.  Efficacy of interleukin-13 receptor–targeted liposomal doxorubicin in the intracranial brain tumor model , 2009, Molecular Cancer Therapeutics.

[72]  R. Pellitteri,et al.  Nose-to-brain delivery: evaluation of polymeric nanoparticles on olfactory ensheathing cells uptake. , 2014, Journal of pharmaceutical sciences.

[73]  W. Jefferies,et al.  Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood–brain barrier , 2005 .

[74]  D. A. Kharkevich,et al.  Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.

[75]  M. Morari,et al.  Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[76]  B. Ruozi,et al.  Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design. , 2012, European journal of medicinal chemistry.

[77]  M. Lanotte,et al.  Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies. , 2014, Journal of pharmaceutical sciences.

[78]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[79]  Liang Jiang,et al.  Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model , 2009, Brain Research.

[80]  Yan Zhang,et al.  Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. , 2009, Molecular pharmaceutics.

[81]  G. Curran,et al.  Development of a Smart Nano-vehicle to Target Cerebrovascular Amyloid Deposits and Brain Parenchymal Plaques Observed in Alzheimer’s Disease and Cerebral Amyloid Angiopathy , 2008, Pharmaceutical Research.

[82]  G. Biggio,et al.  Novel L-Dopa and Dopamine Prodrugs Containing a 2-Phenyl-imidazopyridine Moiety , 2007, Pharmaceutical Research.

[83]  J. Kreuter,et al.  Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[84]  J. Temsamani,et al.  The use of Pep: Trans vectors for the delivery of drugs into the central nervous system , 2005 .

[85]  G. Giammona,et al.  Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. , 2010, Nanomedicine.

[86]  G. Tosi,et al.  Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[87]  R. Straubinger,et al.  Liposome-Mediated Therapy of Intracranial Brain Tumors in a Rat Model , 1997, Pharmaceutical Research.

[88]  B. Ruozi,et al.  Chapter 3 - Colloidal systems for CNS drug delivery. , 2009, Progress in brain research.

[89]  D D Breimer,et al.  The blood-brain barrier in neuroinflammatory diseases. , 1997, Pharmacological reviews.

[90]  R. Mumper,et al.  In Situ Blood–Brain Barrier Transport of Nanoparticles , 2003, Pharmaceutical Research.

[91]  M. Samanta,et al.  Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease , 2008, Brain Research.

[92]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[93]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[94]  S. Cazaubon,et al.  The blood-brain barrier in brain homeostasis and neurological diseases. , 2009, Biochimica et biophysica acta.

[95]  Paul R. Lockman,et al.  In Vivo and in Vitro Assessment of Baseline Blood-Brain Barrier Parameters in the Presence of Novel Nanoparticles , 2003, Pharmaceutical Research.

[96]  Gorka Orive,et al.  Nanotherapeutic approaches for brain cancer management. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[97]  K. Geiger,et al.  Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles , 2004, International journal of cancer.

[98]  K. Tomizawa,et al.  Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. , 2009, Biomaterials.

[99]  G. Storm,et al.  Targeting Anti—Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[100]  J. Kreuter,et al.  Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model , 2006, Journal of microencapsulation.

[101]  D. Maysinger,et al.  Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles , 2003, Science.

[102]  E. Morgan,et al.  Transferrin and Transferrin Receptor Function in Brain Barrier Systems , 2000, Cellular and Molecular Neurobiology.

[103]  J. Au,et al.  Physiologically Based Pharmacokinetic Models of 2′,3′-Dideoxyinosine , 1997, Pharmaceutical Research.

[104]  Michele Zoli,et al.  Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[105]  R. Zhou,et al.  Differential Pharmacodynamic Effects of Paclitaxel Formulations in an Intracranial Rat Brain Tumor Model , 2010, Journal of Pharmacology and Experimental Therapeutics.

[106]  S. Krähenbühl,et al.  Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution and in vitro pharmacological effects , 2005, Journal of drug targeting.

[107]  Xavier Montet,et al.  Interaction of Functionalized Superparamagnetic Iron Oxide Nanoparticles with Brain Structures , 2006, Journal of Pharmacology and Experimental Therapeutics.

[108]  R. Alyautdin,et al.  Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles , 1997 .

[109]  Barbara Ruozi,et al.  Polymeric nanoparticles for the drug delivery to the central nervous system , 2008, Expert opinion on drug delivery.

[110]  M. Samanta,et al.  Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[111]  Y. Eto,et al.  Liposome targeting to mouse brain: mannose as a recognition marker. , 1988, Biochemical and biophysical research communications.

[112]  Giuseppina Raciti,et al.  FA-loaded lipid drug delivery systems: preparation, characterization and biological studies. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[113]  A. Gabizon,et al.  Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. , 1995, Journal of neurosurgery.

[114]  V. Labhasetwar,et al.  Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. , 2004, Molecular pharmaceutics.

[115]  M. Masserini,et al.  Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. , 2011, Nanomedicine : nanotechnology, biology, and medicine.